The clinical performance is complex and often involves multiple systems. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of IBD requires a combination of clinical performance, imaging checks, laboratory checks and pathological evaluations.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. The treatment and management of IBD requires the individualization of treatment programs, typically including drug therapy, rehabilitation interventions, regular follow-up, and more. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of IBD-associated proteins. The platform serves a team of internationally authorized experts in the field of infectious respiratory digestive endocrine systems in China, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.